These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38624443)

  • 1. Innovation drivers of external competitiveness in the great recession.
    Brancati E; Brancati R; Guarascio D; Zanfei A
    Small Bus Econ (Dordr); 2022; 58(3):1497-1516. PubMed ID: 38624443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the growth impact of different eco-innovation business strategies.
    Caravella S; Crespi F
    Econ Polit (Bologna); 2022; 39(2):657-683. PubMed ID: 35422587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey data on organizational resources and capabilities, export marketing strategy, export competitiveness, and firm performance in exporting firms in Indonesia.
    Heriqbaldi U; Jayadi A; Erlando A; Samudro BR; Widodo W; Esquivias MA
    Data Brief; 2023 Jun; 48():109112. PubMed ID: 37101779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forms of extramural research acquisition and product innovation: Data from econometric estimations.
    Carboni OA; Medda G
    Data Brief; 2021 Dec; 39():107567. PubMed ID: 34825033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The speed of internationalization in regionally clustered family firms: a deeper understanding of innovation activities and cluster affiliation.
    Mendes T; Braga V; Silva C; Braga A
    Jahrb Reg Wiss; 2023 Mar; ():1-58. PubMed ID: 38625131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of network positions in scientific collaboration on pharmaceutical firms' technological innovation performance: Moderating roles of scientific collaboration strength and patent stock.
    Wang XX; Jiao HY
    Front Public Health; 2022; 10():980845. PubMed ID: 36033805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey data on growth companies' and control group's perceptions on innovative behavior.
    Suominen A; Pihlajamaa M
    Data Brief; 2022 Aug; 43():108324. PubMed ID: 35692612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does capital structure change product-market competitiveness? Evidence from Chinese firms.
    Li L; Wang Z
    PLoS One; 2019; 14(2):e0210618. PubMed ID: 30721237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Framework to Move Forward on the Path to Eco-innovation in the Construction Industry: Implications to Improve Firms' Sustainable Orientation.
    Segarra-Oña MD; Peiró-Signes A; Cervelló-Royo R
    Sci Eng Ethics; 2015 Dec; 21(6):1469-84. PubMed ID: 25515862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we predict firms' innovativeness? The identification of innovation performers in an Italian region through a supervised learning approach.
    Gandin I; Cozza C
    PLoS One; 2019; 14(6):e0218175. PubMed ID: 31185045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic management and organizational culture of medical device companies in relation to corporate performance.
    Park S; Kim HK; Lee HJ; Choi M; Lee M; Jakovljevic M
    J Med Econ; 2023; 26(1):781-792. PubMed ID: 37300440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEO Overconfidence, Corporate Governance, and R&D Smoothing in Technology-Based Entrepreneurial Firms.
    Huang Y; Wang X; Li Y; Yu X
    Front Psychol; 2022; 13():944117. PubMed ID: 35910989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platform-Based Internationalization of Smaller Firms: The Role of Government Policy.
    Singh N; Munjal S; Kundu S; Rangarajan K
    Manag Int Rev; 2023; 63(1):91-115. PubMed ID: 36465886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marketing innovations during a global crisis: A study of China firms' response to COVID-19.
    Wang Y; Hong A; Li X; Gao J
    J Bus Res; 2020 Aug; 116():214-220. PubMed ID: 32501308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity and state dependence in firms' access to bank credit.
    Aristei D; Angori G
    Small Bus Econ (Dordr); 2022; 59(1):47-78. PubMed ID: 38624968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do R&D intensity and capacity utilisation matter for SMEs' innovations within the CEE region? Testing moderating roles of different ownership structures.
    Darfo-Oduro R; Prokop V; Stejskal J; Klímová V; Žítek V
    PLoS One; 2024; 19(1):e0296873. PubMed ID: 38215159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Schemes for Investment in of Small and Medium-Sized Enterprises of China: Role of Access to Finance, Innovation, and Sustainability.
    Tang X
    Front Psychol; 2022; 13():857193. PubMed ID: 35558710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Collaboration with universities and innovate activity in the Spanish pharmaceutical industry (2003-2005)].
    D'Este P; Tribó JA; García-Romero A
    Med Clin (Barc); 2008 Dec; 131 Suppl 5():66-70. PubMed ID: 19631826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.